Business Categories Reports Podcasts Events Awards Webinars
Contact My Account About

Shiseido Beauty Innovations Fund Closes Its First Deal

August 11, 2022
August 11, 2022
Alex Kondratiev via Unsplash

The Shiseido Beauty Innovations Fund closed its first deal, leading an investment round in Jiangsu Trautec Medical Technology, a Chinese maker of recombinant collagen-based biomaterials.

WHO: Established in 2015, Trautec develops, manufactures, and holds multiple intellectual property rights for recombinant collagen*2-based biomaterials for use in the medical and cosmetics industries. The company controls the entire value chain from research and development to manufacturing and distribution with a Changzhou, Jiangsu Province plant.

Launched in 2019, the Shiseido Beauty Innovations Fund was established by Shiseido Company, Limited's ("Shiseido") China subsidiary, Shiseido China Co., Ltd., and Boyu Capital. Boyu Capital and Shiseido jointly manage the fund to explore investment opportunities in emerging Chinese beauty and wellness brands and related technology companies such as e-commerce services and consumer experience technology.

Through the fund, Shiseido will fuse its values with those of emerging companies to enhance its business portfolio in China to meet diversifying consumer needs and to steadily strengthen the China business, which is one of the pillars of the company's medium- to long-term strategy "WIN 2023 and Beyond."

Founded in 2011, Boyu Capital is a leading alternative asset management firm with offices in Hong Kong, Beijing, Shanghai, and Singapore. Comprising a team of experienced investors and business operators, Boyu provides growth capital and strategic support through long-term partnerships with leading entrepreneurs and enterprises. Its portfolio includes companies in media, technology, consumer goods, retail, financial services, and health care.

WHY: The market for functional skincare is growing significantly as Chinese consumers look for effective solutions to their skin problems. The need for recombinant collagen is expanding because of its stability and effectiveness and wide application in medical, health care, and cosmetics fields.

IN THEIR OWN WORDS: "The market of functional skin care, which offers specific functions to skin, is growing significantly, as more Chinese consumers are looking for effective solutions to their skin problems," added Shiseido. "The needs for recombinant collagen are expanding because of its stability and effectiveness, as well as wide application to medical, health care and cosmetics fields."


  • Shiseido Beauty Innovations Fund invested RMB 100 million into Trautec. 
  • In addition to the investment, Shiseido will form a strategic partnership with the Chinese biomaterials maker to work together in areas such as product research and development, raw material supply, and sales channels to accelerate the exploration of new areas in functional skincare.

2 Article(s) Remaining

Subscribe today for full access